Company Profile
ALK-Abelló A/S, an allergy solutions company, develops treatments for respiratory allergy, anaphylaxis, and food allergy and new disease areas in the European Union, the United Kingdom, Norway, Switzerland, the United States, Canada, Japan, China, and internationally. The company offers allergy immunotherapy products in the form of vaccines, injections, sublingual drops, and tablets for the treatment of various allergies, including grass and tree pollen, house dust mites, ragweed, Japanese cedar, peanuts, and tree nuts; adrenaline nasal sprays for emergency treatment of anaphylaxis and acute flares in chronic spontaneous urticaria; and ALK 014, a biologic for food allergies. It also provides GRAZAX/GRASTEK, a tablet for grass pollen allergy; ACARIZAX, ODACTRA, and MITICURE/SENSIMUNE, which are tablets for house dust mite allergies; ITULAZAX/ITULATEK, a tablet for tree pollen allergy; RAGWITEK/RAGWIZAX, a tablet for ragweed pollen allergy; and CEDARCURE, a tablet for Japanese cedar pollen allergy. In addition, the company offers consumer healthcare solutions, such as klarify.me, a digital patient engagement platform to help people manage their allergies. Further, it provides allergen extracts for use in the diagnosis of specific allergies, such as skin prick and blood test; and emergency medicine treatment, such as adrenaline autoinjectors, an intra-muscular injection of adrenaline for the treatment of acute life-threatening allergic reactions, including anaphylaxis. The company has a collaboration with Torii Pharmaceutical Co., Ltd. for the development of GRAZAX and CEDARCURE; and Dr. Reddy's Laboratories for the development of Sensimune. ALK-Abelló A/S was founded in 1923 and is headquartered in Horsholm, Denmark.
Latest News
| Sector | Healthcare |
| Industry | Biotechnology |
| Website | https://www.alk.net |
| Audit Risk | 3 |
| Board Risk | 2 |
| Overall Risk | 4 |
| Market Cap | 50.57B |
| Trailing P/E | 39.28 |
| Forward P/E | 30.44 |
| Dividend Rate | 1.6 |
| Dividend Yield | 0.70% |
| Trailing Annual Div. Rate | 1.6 |
| Trailing Annual Div. Yield | 0.70% |
| Trailing EPS | 5.81 |
| Forward EPS | 7.5 |
| Book Value | 29.65 |
| Price-to-Book | 7.7 |
| Enterprise-to-Revenue | 7.49 |
| Enterprise-to-EBITDA | 24.41 |
| Ex-Dividend Date | 03/17/2026 |
| Earnings Date | 08/20/2026 |
| Earnings Call Date | 05/04/2026 |
| Earnings Average | 1.5 |
| Earnings Low | 1.5 |
| Earnings High | 1.5 |
| Revenue Average | 1.74B |
| Revenue Low | 1.72B |
| Revenue High | 1.76B |